|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
 Dr Philip Sager,
formerly Vice president and Head Cordio Pulmonary and Metabolic Clinical Department Gilead Dr. Sager is VP, Clinical Research and Head of CV/Metabolic Clinical Development at Gilead Sciences. Prior to joining Gilead he was the Chief Medical Officer of CardioDx, a molecular diagnostics company, Executive Director at AstraZeneca, responsible for worldwide development programs, and a director at the Schering-Plough Research Institute. He played critical roles in the development of Crestor, Vytorin, Zetia, and the anti-platelet agent Brilinta (ticagrelor). Dr. Sager has also been the ICH Expert Working Group PhRMA Topic Leader on the QT interval initiative (ICH E14) and is the co-Chair of the Scientific Oversight Committee of the FDA-sponsored Cardiac Safety Research Consortium, where he is also on the Executive Committee.
Before joining the pharmaceutical industry, Dr. Sager was a tenured faculty member in cardiology at the UCLA School of Medicine and Director of the Arrhythmia Service at the West Los Angeles Veterans Affairs Medical Center. He has published over 150 scientific manuscripts and abstracts and completed his undergraduate education at the Massachusetts Institute of Technology and his medical education and medical training in internal medicine and cardiology at the Yale University School of Medicine. He is a fellow of the American College of Cardiology, the American Heart Association, the American College of Physicians, and the Heart Rhythm Society. Dr. Sager is a member of Alpha Omega Alpha and Phi Beta Kappa.
Appearing: Day One, Wednesday 20 October 2010 4pm Safety Pharmacology Best Practices• Understand how preclinical safety testing can be used
• Early identification of risks and de-risking NCEs
• Design the most efficient early clinical trials Dr Philip Sager, formerly Vice president and Head Cordio Pulmonary and Metabolic Clinical Department,
Gilead |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
